Bio-Techne Corporation (NASDAQ: TECH) saw its stock surge approximately 19% in early trading Thursday after German pharmaceutical and life sciences giant Merck KGaA (ETR: MRK) announced a definitive agreement to acquire the company for $73 per share in cash. The offer, which values Bio-Techne at an enterprise value of $11.3 billion, represents a 36% premium to the stock's one-month volume-weighted average price (VWAP), though only about 24% above Wednesday's closing price of $58.88.
By 9:51 a.m. EDT, Bio-Techne shares were trading at $70.17, leaving a $2.83 spread to the offer price. This gap is typical for merger-arbitrage situations, reflecting the time value of money and the risk that the deal may not close. Merck expects to complete the acquisition in late 2026 or early 2027, pending Bio-Techne shareholder approval and various regulatory clearances.
Trading volume exploded in the first half-hour, with 15.42 million shares changing hands by 9:51 a.m. That volume already surpassed the most recent short interest tally of 13.85 million shares and represented 574% of the 65-day average daily volume. The heavy turnover does not necessarily indicate short covering; rather, it reflects the massive repositioning triggered by the deal announcement.
Merck's acquisition price works out to less than 9.4 times Bio-Techne's projected fiscal 2025 sales, based on the company's guidance of "more than $1.2 billion" in revenue. The German firm plans to fund the purchase through a combination of cash on hand and new debt issuance. Merck also expects to achieve annual cost synergies of approximately €140 million (about $159 million), representing roughly 1.4% of the total enterprise value.
Merck CEO Kai Beckmann described Bio-Techne as an "outstanding fit" for the company's life science division. Jean-Charles Wirth, head of Merck's Life Science business, highlighted that the acquisition adds 6,000 proteins and 425,000 antibodies to Merck's portfolio, calling it a "big, big plus" for customers. Bio-Techne Chairman Robert V. Baumgartner said the deal allows shareholders to "deliver substantial, near-term cash value."
Analyst reactions were mixed. Leerink's Puneet Souda noted that Merck is picking up an "attractive asset with strong long-term potential," while Evercore ISI's Daniel Markowitz called Bio-Techne "an attractive asset." However, William Blair's Matt Larew expressed disappointment with the valuation, telling Investor's Business Daily that the price was "a bit disappointing" and that he didn't see another bidder emerging.
For merger-arbitrage investors, the key metric is the spread between the current stock price and the offer price. At $70.17, the spread of $2.83 implies a gross return of about 4.0% before considering financing costs, fees, and taxes. If the spread widens, it would signal increased skepticism about the deal's completion, while a narrowing spread would indicate growing confidence.
The broader health-care sector also posted gains Thursday, with the iShares U.S. Medical Devices ETF (IHI) adding 1.3%, the Health Care Select Sector SPDR Fund (XLV) climbing 1.6%, and the SPDR S&P Biotech ETF (XBI) rising 1.7%.
